Filtered By:
Therapy: Antiviral Therapy
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 305 results found since Jan 2013.
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
ConclusionsThe addition of sofosbuvir and daclatasvir to standard care significantly reduced the duration of hospital stay compared with standard care alone. Although fewer deaths were observed in the treatment arm, this was not statistically significant. Conducting larger scale trials seems prudent.
Source: Journal of Antimicrobial Chemotherapy - August 19, 2020 Category: Microbiology Source Type: research
Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy.
CONCLUSIONS: This report is the first study evaluating temporized morning vs. evening antiviral administration in SARS-CoV-2 patients. The morning regimen was associated with a significant reduction in CRP values. Further confirmations with larger and multicenter samples of patients could reveal novel potentially useful insights.
PMID: 32767353 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - August 14, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Resolution of coronavirus disease 2019 (COVID-19).
Authors: Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, Majumder AA, Nasim T
Abstract
INTRODUCTION: Coronavirus disease 2019 (COVID-19) was first detected in China in December, 2019, and declared as a pandemic by the World Health Organization (WHO) on March 11, 2020. The current management of COVID-19 is based generally on supportive therapy and treatment to prevent respiratory failure. The effective option of antiviral therapy and vaccination are currently under evaluation and development.
AREAS COVERED: A literature search was performed using PubMed between December 1, 2019-June 23, 2020. This...
Source: Expert Review of Anti-Infective Therapy - August 13, 2020 Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Corticosteroid, oseltamivir and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019
ConclusionSymptoms of patients from Tianmen are relatively mild. Treatment should be started as early as possible, but corticosteroid and oseltamivir should be initiated with caution. In addition, clinical trials on arbidol should be conducted to demonstrate its effectiveness.
Source: The Clinical Respiratory Journal - August 12, 2020 Category: Respiratory Medicine Authors: Fuying Hu,
Gang Yin,
Youping Chen,
Jiangqin Song,
Maosong Ye,
Jie Liu,
Cuicui Chen,
Yuanlin Song,
Xinjun Tang,
Yong Zhang Tags: ORIGINAL ARTICLE Source Type: research
Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019
ConclusionSymptoms of patients from Tianmen are relatively mild. Treatment should be started as early as possible, but corticosteroid and oseltamivir should be initiated with caution. In addition, clinical trials on arbidol should be conducted to demonstrate its effectiveness.
Source: The Clinical Respiratory Journal - August 3, 2020 Category: Respiratory Medicine Authors: Fuying Hu,
Gang Yin,
Youping Chen,
Jiangqin Song,
Maosong Ye,
Jie Liu,
Cuicui Chen,
Yuanlin Song,
Xinjun Tang,
Yong Zhang Tags: ORIGINAL ARTICLE Source Type: research
Understanding and implementing alternative solutions to address the COVID-19 pandemic in the sense of public health emergencies.
Authors: Bhole RP, Sarode VI, Bonde CG
Abstract
The Coronavirus disease (COVID-19) caused by the novel SARS-CoV-2 coronavirus has spread from China and quickly transmitted to most other countries around the world. The World Health Organization announced COVID-19 as a pandemic that is spreading steadily and soon in most states. Coronavirus genomic characterization showed that it most closely resembled another bat-origin beta-coronavirus. Coronavirus has the largest genome of viruses that have RNA. Spike (S) glycoprotein is present in the virus and is responsible for virus entry into the host cell. COVID-19 can sprea...
Source: European Review for Medical and Pharmacological Sciences - July 28, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath.
Abstract
Outbreak of Coronavirus disease 2019 (COVID-19) started in mid of December 2019 and spread very rapidly across the globe within a month of its outbreak. Researchers all across the globe started working to find out its possible treatments. However, most of initiatives taken were based on various hypotheses and till date no successful treatments have been achieved. Some strategies adopted by China where existing antiviral therapy was initially used to treat COVID-19 have not given very successful results. Researchers from Thailand explored the use of combination of anti-influenza drugs such as Oseltamivir, ...
Source: European Journal of Pharmacology - July 24, 2020 Category: Drugs & Pharmacology Authors: Awasthi A, Vishwas S, Corrie L, Kumar R, Khursheed R, Kaur J, Kumar R, Arya KR, Gulati M, Kumar B, Singh SK, Pandey NK, Wadhwa S, Kumar P, Kapoor B, Gupta RK, Kumar A Tags: Eur J Pharmacol Source Type: research
Multiple sclerosis and COVID-19.
Authors: Mares J, Hartung HP
Abstract
This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment;...
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - July 21, 2020 Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research
Re: “early outpatient treatment of symptomatic, high-risk covid-19 patients that should be ramped up immediately as key to the pandemic crisis”
In his recent article, Dr. Harvey Risch (1) makes an impassioned plea that we are unable to wait for results from randomized controlled trials of coronavirus disease 2019 (COVID-19) and should immediately roll out early outpatient treatment with hydroxychloroquine (HCQ) and azithromycin (AZ). Early treatment that prevents disease progression and hospitalization is desperately needed, and timing of initiation of antiviral therapy may have important effects on the outcomes of therapy for COVID-19 (2). Unfortunately, as Risch states, “based on laboratory and other preliminary evidence available to date,” no available trea...
Source: American Journal of Epidemiology - July 20, 2020 Category: Epidemiology Source Type: research
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
ConclusionsOur results indicate that there are no significant differences among the three regimens in terms of antiviral effectiveness in patients with mild to moderate COVID-19. Furthermore, the combination of RBV and LPV/r is associated with a significant increase in gastrointestinal adverse events, suggesting that RBV and LPV/r should not be co-administered to COVID-19 patients simultaneously.Clinical Trial Registrationwww.ClinicalTrials.gov, ID: ChiCTR2000029387. Registered on January 28, 2019.
Source: Frontiers in Pharmacology - July 13, 2020 Category: Drugs & Pharmacology Source Type: research
Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions
Publication date: Available online 10 July 2020Source: Antiviral ResearchAuthor(s): So Young Kim, Weihua Jin, Amika Sood, David W. Montgomery, Oliver C. Grant, Mark M. Fuster, Li Fu, Jonathan S. Dordick, Robert J. Woods, Fuming Zhang, Robert J. Linhardt
Source: Antiviral Therapy - July 10, 2020 Category: Virology Source Type: research
Pathological Aspects of COVID-19 as a Conformational Disease and the Use of Pharmacological Chaperones as a Potential Therapeutic Strategy
Coronavirus disease 2019 (COVID-19), the seventh human coronavirus infectious disease, was first reported in Wuhan, China, in December 2019, followed by its rapid spread globally (251,059 deaths, on May 5, 2020, by Johns Hopkins University). An early clinical report showed that fever, cough, fatigue, sputum production, and myalgia were initial symptoms, with the development of pneumonia as the disease progressed. Increases in the level of serum liver enzymes, D-dimer, cardiac troponin I, and creatinine have been observed in severely ill patients, indicating that multiple organ failure had occurred in these cases. Lymphopen...
Source: Frontiers in Pharmacology - July 9, 2020 Category: Drugs & Pharmacology Source Type: research
Current Therapies Under Investigation for COVID-19.
Abstract
In response to the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers are expeditiously searching for antiviral treatments able to alleviate the symptoms of infection, which can be life-threatening. Here, we provide a general overview of what is currently known about the structure and characteristic features of SARS-CoV-2, some of which could potentially be exploited for the purposes of antiviral therapy and vaccine development. This mini-review also covers selected and noteworthy antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or t...
Source: Canadian Journal of Physiology and Pharmacology - July 7, 2020 Category: Drugs & Pharmacology Authors: Weisberg E, Sattler M, Yang PL, Parent A, Gray N, Griffin JD Tags: Can J Physiol Pharmacol Source Type: research
Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019
Publication date: October 2020Source: Pharmacological Research, Volume 160Author(s): Xin Li, Yi Yang, Lancong Liu, Xuefeng Yang, Xiaobo Zhao, Yan Li, Yanyan Ge, Yuxin Shi, Ping Lv, Jianchu Zhang, Tao Bai, Hua Zhou, Pei Luo, Shilong Huang
Source: Pharmacological Research - July 5, 2020 Category: Drugs & Pharmacology Source Type: research
Primer design for quantitative real-time PCR for the emerging Coronavirus SARS-CoV-2
In December 2019, a new coronavirus disease (COVID-19) outbreak occurred in Wuhan, China. Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), which is the seventh coronavirus known to infect humans, is highly contagious and has rapidly expanded worldwide since its discovery. Quantitative nucleic acid testing has become the gold standard for diagnosis and guiding clinical decisions regarding the use of antiviral therapy. However, the RT-qPCR assays targeting SARS-CoV-2 have a number of challenges, especially in terms of primer design. Primers are the pivotal components of a RT-qPCR assay. Once virus mutation and r...
Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Dandan Li, Jiawei Zhang, Jinming Li Tags: Review Source Type: research
